Elekta completes the acquisition of CMS

Stockholm, Sweden, March 04, 2008

The international medical technology group Elekta AB (publ) (STO: EKTAb) today announced the completion of its announced acquisition of CMS, Inc. for total cash consideration representing an enterprise value of USD 75 M.

CMS is a worldwide leader in the development, sales and support of advanced radiation therapy planning solutions, supporting over 1,500 sites in clinical operation throughout the world.

CMS, with several leading solutions in clinical use and a strong pipeline of advanced functionality in development, will significantly contribute to Elekta’s strategy in radiation therapy planning and management of images and information. CMS’s large, highly competent sales, marketing, product creation and support organizations will provide added resources and expertise to enable Elekta to accelerate the development of new cancer treatment solutions and bring these tools to market more quickly and effectively.

From a financial reporting perspective CMS will be consolidated into Elekta’s accounts as of March 4, 2008.

As previously communicated, based on a preliminary purchase price allocation together with a conservative estimation of revenue synergies, Elekta’s management expect the acquisition to result in:

• Accretion to earnings on a cash basis in fiscal year 2008/09 and onwards
• Neutral effect on EPS in fiscal year 2008/09 and accretion thereafter
• Accelerated revenue growth, but with modest group effect given the size of the acquired business
• Preserved balance sheet strength and financial flexibility

About Elekta

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta’s solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT ). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world’s largest supplier of oncology software.

Elekta’s systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approx. 2,000 employees, Elekta’s corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please click here.

For further information, please contact:

Investor Enquiries:

Peter Ejemyr, Group VP Corporate Communications.
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com